UNIVERSITY OF KINSHASA

Bavarian Nordic Initiates First Clinical Trials of Mpox Vaccine in Infants and Pregnant Women

- Bavarian Nordic has launched two groundbreaking clinical trials to evaluate the safety and immunogenicity of MVA-BN mpox vaccine in 344 infants aged 4-24 months and 359 pregnant or breastfeeding women. - Both studies are being conducted in the Democratic Republic of Congo, the epicenter of the ongoing mpox outbreak, where these vulnerable populations remain at high risk. - The trials are part of the PregInPoxVac research project and could support regulatory approval to expand MVA-BN vaccine access to the most vulnerable populations. - Results from a concurrent pediatric trial in children aged 2-11 years are expected in Q3 2025, potentially supporting broader age group approvals.